Sensitivity and specificity of cystic fibrosis-related diabetes screening methods: which test should be the reference method?

Boudreau, Valérie; Dubois, Catherine; Desjardins, Katherine; Mailhot, M.; Tremblay, François; Rabasa‐Lhoret, Rémi

doi:10.1515/jpem-2017-0122

Cited by 8 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alongside the reduction in insulin needs, weight gain and improvement in respiratory function were observed. We assumed that HOMA2 could be used to assess glucose homeostasis determinants in the context of CF based on previous studies [35] , [36] , [37] , [38] , [39] . Of note, there were no significant changes in HOMA-derived estimates of BCF and IS in patients without diabetes after treatment with CFTR modulators, even though they gained weight and improved lung function.…”

Section: Discussionmentioning

confidence: 99%

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes

Lurquin

Gohy

Hermans

et al. 2023

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes

Lurquin

Gohy

Hermans

et al. 2023

Journal of Clinical & Translational Endocrinology

View full text Add to dashboard Cite

“…Therefore, HbA 1c may not detect CFRD and its complications until late. Moreover, most evidence suggests that the diagnostic threshold for CFRD, HbA 1c ≥6.5%, has poor sensitivity compared to OGTT [54,[83][84][85].…”

Section: Hba 1cmentioning

confidence: 99%

“…All these parameters have been correlated with HbA 1c in CF patients [75], and many have been correlated with clinical outcomes. However, these studies report heterogeneous findings and rarely include substantial prospective follow-up (see Section 3) [84].…”

Section: Continuous Glucose Monitoringmentioning

confidence: 99%

Detection and Management of Early Glucose Abnormalities in Cystic Fibrosis

Theocharous¹,

Prentice²,

Verge³

et al. 2021

Cystic Fibrosis - Facts, Management and Advances

View full text Add to dashboard Cite

With advances in technology, it is now possible to detect the emergence of glucose abnormalities in cystic fibrosis with improved sensitivity, and from a very early age. These abnormalities are increasingly recognized as predictors of clinical decline, raising the possibility that early intervention may slow or prevent this deterioration. In this chapter, we will review the available literature on methods of detecting glucose abnormalities in cystic fibrosis (random and fasting glucose, HbA1c, oral glucose tolerance testing, and continuous glucose monitoring), and detail their advantages and possible limitations in the interpretation of glycemic data. We will also discuss treatment outcomes of early intervention, prior to the diagnosis of diabetes as currently defined.

show abstract

“…Sensitivity and specificity of cystic fibrosis-related diabetes screening methods were studied by Valérie Boudreau and colleagues [6]. New consensus guidelines will have to follow and will hopefully improve care and prognosis of patients with CF.…”

mentioning

confidence: 99%